2016
DOI: 10.3171/2016.3.focus1667
|View full text |Cite
|
Sign up to set email alerts
|

Magnetic resonance imaging assessment of degenerative cervical myelopathy: a review of structural changes and measurement techniques

Abstract: Degenerative cervical myelopathy encompasses a spectrum of age-related structural changes of the cervical spine that result in static and dynamic injury to the spinal cord and collectively represent the most common cause of myelopathy in adults. Although cervical myelopathy is determined clinically, the diagnosis requires confirmation via imaging, and MRI is the preferred modality. Because of the heterogeneity of the condition and evolution of MRI technology, multiple techniques have been developed ove… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
134
0
5

Year Published

2017
2017
2023
2023

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 159 publications
(140 citation statements)
references
References 131 publications
(146 reference statements)
1
134
0
5
Order By: Relevance
“…Although previously used diagnostic criteria for DCM were neither standardized nor consistent across published studies, recent and current studies have defined DCM by the presence of at least one neurological sign and at least one neurological symptom in addition to a positive MRI for compression of the cord(Amenta et al, 2014;Kalsi-Ryan, Karamidas, & Fehlings, 2013).Definition of MRI criteria for degenerative cervical cord compression is essential for reliable and reproducible diagnosis of DCM. In general, spinal cord compression can be described based on the appearance or by measuring a ratio between the anteroposterior diameter at the compressed site and that of a noncompressed site, a ratio between the anteroposterior diameter and the transverse diameter (i.e., CR), or CSA at the region of compression(Nouri, Martin, Mikulis, & Fehlings, 2016). MRI T1/T2 signal changes, although frequently detected in DCM, are neither sensitive nor specific for degenerative cervical cord compression and are invaluable to the diagnosis of DCM (Kalsi-Ryan et al, 2013;Wilson et al, 2013).…”
mentioning
confidence: 99%
“…Although previously used diagnostic criteria for DCM were neither standardized nor consistent across published studies, recent and current studies have defined DCM by the presence of at least one neurological sign and at least one neurological symptom in addition to a positive MRI for compression of the cord(Amenta et al, 2014;Kalsi-Ryan, Karamidas, & Fehlings, 2013).Definition of MRI criteria for degenerative cervical cord compression is essential for reliable and reproducible diagnosis of DCM. In general, spinal cord compression can be described based on the appearance or by measuring a ratio between the anteroposterior diameter at the compressed site and that of a noncompressed site, a ratio between the anteroposterior diameter and the transverse diameter (i.e., CR), or CSA at the region of compression(Nouri, Martin, Mikulis, & Fehlings, 2016). MRI T1/T2 signal changes, although frequently detected in DCM, are neither sensitive nor specific for degenerative cervical cord compression and are invaluable to the diagnosis of DCM (Kalsi-Ryan et al, 2013;Wilson et al, 2013).…”
mentioning
confidence: 99%
“…11,[21][22][23][24][25] These encouraging findings prompted the current study in degenerative cervical myelopathy (DCM), a common condition involving degeneration of the discs, ligaments, and vertebrae, resulting in cervical spinal cord compression and functional impairment (Fig 1). 26,27 We aimed to determine how well T2*WI WM/GM differs between patients with DCM and healthy subjects and correlates with global disability and focal neurologic deficits when extracted from corresponding regions of WM, in comparison with FA, MTR, and CSA of the SC.…”
mentioning
confidence: 99%
“…[6][7][8] MUCCA has been found to be robust at the C1-C2 and C2-C3 intervertebral levels. 9,10 However, there is little consensus on how reliable it is longitudinally or whether SC atrophy measures are ready for use as a clinical trial end point and/or for patient monitoring in neuroinflammatory diseases, 11,12 SC injury, 13,14 or degenerative cervical myelopathy, 15 among other diseases affecting the SC. Most studies of MR imaging-based SC atrophy comparisons of diseased with healthy SC measures have relied on interindividual variability calculated from crosssectional data.…”
Section: Discussionmentioning
confidence: 99%